Australia - English - Department of Health (Therapeutic Goods Administration)

bristol-myers squibb australia pty ltd - daclatasvir dihydrochloride -

Australia - English - Department of Health (Therapeutic Goods Administration)

bristol-myers squibb australia pty ltd - daclatasvir dihydrochloride -

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

synerrv sdn bhd - daclatasvir dihydrochloride -

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

synerrv sdn bhd - daclatasvir dihydrochloride -

New Zealand - English - Medsafe (Medicines Safety Authority)

bristol-myers squibb (nz) limited - daclatasvir dihydrochloride 33mg equivalent to daclatasvir 30mg - tablet - 30 mg - active: daclatasvir dihydrochloride 33mg equivalent to daclatasvir 30mg excipient: colloidal silicon dioxide croscarmellose sodium lactose magnesium stearate microcrystalline cellulose opadry green - daklinza is indicated in combination with other medicinal products for the treatment of chronic hepatitis c virus (hcv) infection in adults with compensated liver disease (including cirrhosis).

New Zealand - English - Medsafe (Medicines Safety Authority)

bristol-myers squibb (nz) limited - daclatasvir dihydrochloride 66mg equivalent to daclatasvir 60mg - tablet - 60 mg - active: daclatasvir dihydrochloride 66mg equivalent to daclatasvir 60mg excipient: colloidal silicon dioxide croscarmellose sodium lactose magnesium stearate microcrystalline cellulose opadry green - daklinza is indicated in combination with other medicinal products for the treatment of chronic hepatitis c virus (hcv) infection in adults with compensated liver disease (including cirrhosis).

Canada - English - Health Canada

bristol-myers squibb canada - daclatasvir (daclatasvir dihydrochloride) - tablet - 30mg - daclatasvir (daclatasvir dihydrochloride) 30mg - hcv replication complex inhibitors

Canada - English - Health Canada

bristol-myers squibb canada - daclatasvir (daclatasvir dihydrochloride) - tablet - 60mg - daclatasvir (daclatasvir dihydrochloride) 60mg - hcv replication complex inhibitors

United States - English - NLM (National Library of Medicine)

e.r. squibb & sons, l.l.c. - daclatasvir dihydrochloride (unii: 50zo25c11d) (daclatasvir - unii:li2427f9ci) - daclatasvir 90 mg - daklinza is indicated for use with sofosbuvir, with or without ribavirin, for the treatment of patients with chronic hepatitis c virus (hcv) genotype 1 or genotype 3 infection [see dosage and administration (2) and clinical studies (14) ]. limitations of use: anticonvulsants phenytoin, carbamazepine may lead to loss of virologic response to daklinza antimycobacterial agents rifampin herbal products st. john’s wort (hypericum perforatum )                no adequate human data are available to determine whether or not daklinza poses a risk to pregnancy outcomes. in animal reproduction studies in rats and rabbits, no evidence of fetal harm was observed with oral administration of daclatasvir during organogenesis at doses that produced exposures up to 6 and 22 times, respectively, the recommended human dose (rhd) of 60 mg of daklinza. however, embryofetal toxicity was observed in rats and rabbits at maternally toxic doses that produced exposures of 33 and 98 times the human exposure, respectively, at the rhd of 6

Kenya - English - Pharmacy and Poisons Board

mylan laboratories limited mylan laboratories limited. plot no.564/a/22, - daclatasvir and sofosbuvir film-coated tablets 60… - film-coated tablet - each film-coated tablet contains: daclatasvir… - daclatasvir